PL2822947T3 - Sole argininowe agonisty TLR7 - Google Patents

Sole argininowe agonisty TLR7

Info

Publication number
PL2822947T3
PL2822947T3 PL13708142T PL13708142T PL2822947T3 PL 2822947 T3 PL2822947 T3 PL 2822947T3 PL 13708142 T PL13708142 T PL 13708142T PL 13708142 T PL13708142 T PL 13708142T PL 2822947 T3 PL2822947 T3 PL 2822947T3
Authority
PL
Poland
Prior art keywords
tlr7 agonist
arginine salts
arginine
salts
tlr7
Prior art date
Application number
PL13708142T
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Siddartha Jain
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL2822947T3 publication Critical patent/PL2822947T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13708142T 2012-03-07 2013-03-07 Sole argininowe agonisty TLR7 PL2822947T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
PL2822947T3 true PL2822947T3 (pl) 2017-01-31

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13708142T PL2822947T3 (pl) 2012-03-07 2013-03-07 Sole argininowe agonisty TLR7

Country Status (18)

Country Link
US (1) US9320748B2 (pl)
EP (1) EP2822947B1 (pl)
JP (1) JP6325986B2 (pl)
CN (1) CN104203946B (pl)
AU (1) AU2013229466A1 (pl)
CA (1) CA2865759C (pl)
CY (1) CY1118091T1 (pl)
DK (1) DK2822947T3 (pl)
ES (1) ES2597755T3 (pl)
HR (1) HRP20161354T1 (pl)
HU (1) HUE030175T2 (pl)
LT (1) LT2822947T (pl)
MX (1) MX346678B (pl)
PL (1) PL2822947T3 (pl)
PT (1) PT2822947T (pl)
RU (1) RU2014140336A (pl)
SI (1) SI2822947T1 (pl)
WO (1) WO2013131985A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
SG11201606887WA (en) 2014-03-26 2016-09-29 Glaxosmithkline Biolog Sa Mutant staphylococcal antigens
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US20230110516A1 (en) * 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
WO1996001273A1 (en) 1994-07-01 1996-01-18 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
SI2353608T1 (sl) 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
EP1891096A2 (en) 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
CA3154626A1 (en) 2009-04-14 2010-10-21 Glaxosmithkline Biologicals S.A. Compositions for immunising against staphylococcus aureus
US8609106B2 (en) 2009-06-01 2013-12-17 Novartis Ag Combinations of pneumococcal RrgB clades
EP2440245B1 (en) * 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
CN104650241A (zh) 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
SG178954A1 (en) * 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
US20120177681A1 (en) * 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
JP2014525429A (ja) * 2011-09-01 2014-09-29 ノバルティス アーゲー Staphylococcusaureus抗原のアジュバント添加処方物

Also Published As

Publication number Publication date
EP2822947B1 (en) 2016-08-03
AU2013229466A1 (en) 2014-09-04
HUE030175T2 (en) 2017-04-28
PT2822947T (pt) 2016-09-26
CN104203946B (zh) 2017-03-22
DK2822947T3 (en) 2016-09-19
MX346678B (es) 2017-03-29
RU2014140336A (ru) 2016-04-27
CY1118091T1 (el) 2017-06-28
LT2822947T (lt) 2016-10-10
CA2865759A1 (en) 2013-09-12
WO2013131985A1 (en) 2013-09-12
HRP20161354T1 (hr) 2016-12-02
US9320748B2 (en) 2016-04-26
CN104203946A (zh) 2014-12-10
EP2822947A1 (en) 2015-01-14
MX2014010423A (es) 2014-09-22
CA2865759C (en) 2020-07-21
JP6325986B2 (ja) 2018-05-16
US20150125475A1 (en) 2015-05-07
SI2822947T1 (sl) 2016-10-28
JP2015511957A (ja) 2015-04-23
ES2597755T3 (es) 2017-01-20

Similar Documents

Publication Publication Date Title
ZA201401884B (en) New dihydroquinoline-2-one derivatives
LT2822947T (lt) Tlr7 agonisto arginino druskos
EP2970081A4 (en) SALTS OF TREPROSTINIL
GB201304499D0 (en) Carcainium Salts
SG11201401937YA (en) New aryl-quinoline derivatives
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201308401B (en) Substituted benzamide derivatives
ZA201409327B (en) Solid forms of a pyrido-pyrimidinium inner salt
IL231269A0 (en) Preparations for the treatment of HIV
ZA201406238B (en) Crystalline form of a succinate salt
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
IL237382A0 (en) Salts of a benzothiazolone compound as beta-2 adrenergic receptor agonists
PL2760822T3 (pl) Sole desfezoterodyny
ZA201308872B (en) Use of a dinitromethane salt
GB201100332D0 (en) Monty Izofit
ZA201205358B (en) Use of a salt of bistetrazolylamine
GB201106819D0 (en) Novel salts
GB201209895D0 (en) Use of a composition
GB201219868D0 (en) Facilitating completion of a form
GB201204590D0 (en) Prodrugs of thiazolamine compounds